Scholarlink

<p>This study assessed the cost-effectiveness of encorafenib plus cetuximab (EC) and EC combined with mFOLFOX6 versus standard of care (SOC) as first-line treatment for <i>BRAF V600E</i>-mutant metastatic colorectal cancer from a Chinese healthcare perspective. Using a partitioned survival model with data from the BREAKWATER trial, we found that compared to SOC, the incremental cost-effectiveness ratios for EC and EC plus mFOLFOX6 were 77,589.95 per quality-adjusted life year (QALY) and 82,419.06 per QALY, respectively, both exceeding the willingness-to-pay threshold of $40,343.68/QALY. At this threshold, SOC had a 95.43% probability of being cost-effective against EC, and 99.64% against EC plus mFOLFOX6. We conclude that neither EC nor EC plus mFOLFOX6 is cost-effective in China at current prices, suggesting the price negotiations would be necessary to improve their economic value.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China

  • 期刊论文

  • 发表日期：

    2026年5月25日

查看全文
  • Shaohong Luo,
  • Yijun Cai,
  • Xiangzhen Wang,
  • Hong Lan,
  • Lijing Yang,
  • Shen Lin,
  • Xiaoting Huang,
  • Xiuhua Weng,
  • Xiongwei Xu

摘要

This study assessed the cost-effectiveness of encorafenib plus cetuximab (EC) and EC combined with mFOLFOX6 versus standard of care (SOC) as first-line treatment for BRAF V600E-mutant metastatic colorectal cancer from a Chinese healthcare perspective. Using a partitioned survival model with data from the BREAKWATER trial, we found that compared to SOC, the incremental cost-effectiveness ratios for EC and EC plus mFOLFOX6 were 77,589.95 per quality-adjusted life year (QALY) and 82,419.06 per QALY, respectively, both exceeding the willingness-to-pay threshold of $40,343.68/QALY. At this threshold, SOC had a 95.43% probability of being cost-effective against EC, and 99.64% against EC plus mFOLFOX6. We conclude that neither EC nor EC plus mFOLFOX6 is cost-effective in China at current prices, suggesting the price negotiations would be necessary to improve their economic value.